The impact of COVID-19 and other factors on the usage status of the biologic drug therapies for rheumatoid arthritis: A study from Vietnam Hai-Binh Bui; Hong-Thinh Lai; Thanh-Lam Nguyen; Thuy-Duong Vu; Nhat-Le Bui; Van-Hung Nguyen; Thi-To-Chau Tran; Thi-Phuong-Thuy Nguyen; Thi-Ngoc-Lan Nguyen; Jaffar A. Al-Tawfiq; Dinh-Toi Chu;

Can we predict the risk factors for switching due to ineffectiveness in the first year of therapy with bDMARD in patients with rheumatoid arthritis? Ana Martins; Sofia Pimenta; Daniela Oliveira; Rafaela Nicolau; Alexandra Bernardo; Teresa Martins Rocha; Lúcia Costa; Miguel Bernardes;

Patient-reported outcomes in RA patients treated with tofacitinib or bDMARDs in real-life conditions in two Latin American countries J.M. Reyes; M.V. Gutierrez; H. Madariaga; W. Otero; R. Guzman; J. Izquierdo; M. Abello; P. Velez; D. Castillo; D. Ponce de Leon; T. Lukic; L. Amador;